ProfileGDS5678 / 1445825_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 4% 4% 4% 4% 4% 4% 4% 4% 4% 4% 4% 4% 4% 4% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.046934
GSM967853U87-EV human glioblastoma xenograft - Control 22.021774
GSM967854U87-EV human glioblastoma xenograft - Control 32.02214
GSM967855U87-EV human glioblastoma xenograft - Control 41.972034
GSM967856U87-EV human glioblastoma xenograft - Control 51.965324
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.063774
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.025054
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 31.999614
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 41.990244
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.010564
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.00724
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 31.994684
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.011024
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.01024